Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview

Fischer, Peter M. (2017) Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview. Medicinal Research Reviews, 37 (2). pp. 314-367. ISSN 1098-1128

[img] PDF - Repository staff only until 24 October 2017. - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (3MB)

Abstract

Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and pharmacology and the first small-molecule kinase inhibitor, imatinib, was approved for clinical use only 15 years ago. Since then, 33 more kinase inhibitor drugs have received regulatory approval for the treatment of a variety of cancers and the volume of reports on the discovery and development of kinase inhibitors has increased to an extent where it is now difficult—even for those working in the field—easily to keep an overview of the compounds that are being developed, as currently there are 231 such compounds, targeting 38 different protein and lipid kinases (not counting isoforms), in clinical use or under clinical investigation. The purpose of this review is thus to provide an overview of the biomedical rationales for the kinases being targeted on the one hand, and the design principles, as well as chemical, pharmacological, pharmaceutical, and toxicological kinase inhibitor properties, on the other hand. Two issues that are especially important in kinase inhibitor research, target selectivity and drug resistance, as well as the underlying structural concepts, are discussed in general terms and in the context of relevant kinases and their inhibitors.

Item Type: Article
Additional Information: This is the peer reviewed version of the following article: Fischer, P. M. (2016), Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. Med. Res. Rev, which has been published in final form at http://dx.doi.org/10.1002/med.21409. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Keywords: Cancer, Oncology, Kinase inhibitor, Experimental drug, Drug design, Clinical trials
Schools/Departments: University of Nottingham, UK > Faculty of Science > School of Pharmacy
Identification Number: 10.1002/med.21409
Depositing User: Eprints, Support
Date Deposited: 25 Oct 2016 10:33
Last Modified: 18 Mar 2017 19:08
URI: http://eprints.nottingham.ac.uk/id/eprint/37903

Actions (Archive Staff Only)

Edit View Edit View